Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19
December 03 2021 - 03:00PM
Dow Jones News
By Michael Dabaie
Merck & Co. Inc. said it is in a supply agreement with the
Canadian government for up to 1 million patient courses of
molnupiravir, its investigational oral antiviral medicine for the
treatment of Covid-19.
Merck is developing molnupiravir in collaboration with Ridgeback
Biotherapeutics.
The government of Canada secured access in 2022 to 500,000
patient courses, with options for up to 500,000 more, pending
Health Canada approval.
In November, Merck Canada filed the final wave of the
molnupiravir rolling submission to Health Canada, which will decide
on the therapy's approval when all necessary evidence has been
reviewed.
The U.S. Food and Drug Administration's Antimicrobial Drugs
Advisory Committee recently voted 13-10 that the known and
potential benefits of molnupiravir outweigh its known and potential
risks for the treatment of mild to moderate Covid-19 in high-risk
adult patients. While the FDA isn't bound by the committee's
guidance, it takes that advice into consideration.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 03, 2021 14:45 ET (19:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024